Lyell Immunopharma, a preclinical biotech developing T cell therapies for solid tumors, filed on Tuesday with the SEC to raise up to $150 million in an initial public offering.
Lyell states that it is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The company's proprietary genetic and epigenetic reprogramming technologies, Gen-R and Epi-R, are designed to be applied in a target and modality agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL), and T cell receptor (TCR) therapies. Lyell is building a multi-modality pipeline across several solid tumor indications with high unmet needs and anticipates submitting four INDs by the end of 2022.
The South San Francisco, CA-based company was founded in 2018 and booked $9 million in revenue for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol LYEL. Goldman Sachs, BofA Securities, J.P. Morgan, and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.
